Table 2 Multivariate analyses of inflammatory indexes as predictors of platinum-free interval.

From: Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study

 

PFI (< 6 months)

PFI (< 12 months)

OR (95% CI)*

p*

OR (95% CI)*

p*

Overall population

NLR

  < 3

1.00

0.006

1.00

0.036

  ≥ 3

2.52 (1.30–4.87)

 

2.05 (1.05–4.01)

 

SII

    

  < 730

1.00

0.413

1.00

0.786

  ≥ 730

0.74 (0.36–1.53)

 

0.91 (0.45–1.84)

 

CT group

NLR

  < 3

1.00

0.004

1.00

0.027

  ≥ 3

2.77 (1.38–5.56)

 

2.27 (1.10–4.70)

 

SII

    

  < 730

1.00

0.498

1.00

0.663

  ≥ 730

0.76 (0.35–1.67)

 

0.84 (0.39–1.82)

 

CTB group

NLR

  < 3

1.00

0.538

1.00

0.774

  ≥ 3

0.47 (0.04–5.15)

 

0.75 (0.11–5.25)

 

SII

  < 730

1.00

0.696

1.00

0.599

  ≥ 730

1.65 (0.13–20.56)

 

1.78 (0.21–15.14)

 
  1. CI, confidence interval; CT, chemotherapy; CTB, chemotherapy with bevacizumab; NLR, neutrophil-to-lymphocyte ratio; OR, odd ratio; PFI, platinum-free interval; SII, systemic immune-inflammation index.
  2. *Adjusted for ECOG performance status, histology, stage and ascites.
Back to article page